Targeting 3-mercaptopyruvate sulfurtransferase induces cancer stem cell death

This study identifies 3-mercaptopyruvate sulfurtransferase (3-MST) as a critical metabolic vulnerability in colorectal cancer stem cells, demonstrating that its inhibition disrupts bioenergetics and membrane integrity to induce cell death and suppress tumor growth.

The Gist

The Big Picture: Finding the "Achilles' Heel" of Cancer's Immune System

Imagine a colony of cancer cells as a bustling city. Most of the city is made up of regular, fast-growing workers (the main tumor mass). But hidden inside are the "Cancer Bosses" (Cancer Stem Cells or CSCs). These are the troublemakers who can rebuild the whole city if you destroy the workers. They are stubborn, they hide well, and they are incredibly hard to kill with standard chemotherapy.

This paper discovers a secret weakness in these "Cancer Bosses." It turns out they rely heavily on a specific machine called 3-MST to keep their lights on and their defenses up. When the researchers broke this machine, the bosses didn't just get sick; their entire city collapsed.

---

The Key Characters and Concepts

1. The "Cancer Bosses" (Cancer Stem Cells)

Think of these cells as the sleeping dragons in the tumor.

• The Problem: They move slowly and don't grow fast, which is why normal chemotherapy (which targets fast-growing cells) misses them. They are also very tough, with "armor-plated" cell membranes.
• The Discovery: The researchers found that these dragons have a massive, overactive hydrogen sulfide factory (an enzyme called 3-MST). While normal cancer cells have a small generator, these bosses have a giant power plant running 24/7.

2. The "Power Plant" (3-MST and Hydrogen Sulfide)

Hydrogen sulfide is a gas (it smells like rotten eggs), but in the body, it acts like a lubricant and a shield.

• The "Cancer Bosses" use this gas to keep their energy engines running smoothly, even when they are "sleeping" (not dividing).
• They also use it to keep their cell walls (membranes) stiff and rigid, like a tank, so drugs can't get in.

3. The "Saboteur" (The Drug HMPSNE)

The researchers developed a drug (HMPSNE) that acts like a wrench thrown into the gears of the 3-MST power plant.

• What happened? When they turned off the power plant in the "Cancer Bosses," the results were catastrophic for the cancer, but manageable for normal cells.

---

What Happened When They Turned Off the Power?

When the researchers used the drug to stop the 3-MST enzyme, three major things happened to the Cancer Bosses:

1. The Energy Grid Went Dark (Bioenergetic Collapse)

Imagine the cancer cell as a house. The "Cancer Bosses" were already living on a very tight budget, barely having enough electricity to keep the lights on.

• The Effect: When the researchers cut the power (inhibited 3-MST), the house didn't just dim; it went completely dark. The cell's ability to breathe (oxidative phosphorylation) and burn sugar (glycolysis) stopped entirely.
• Why it matters: Normal cancer cells had a backup generator, so they survived. But the "Bosses," who were already running on a shoestring budget, couldn't survive without that specific power source.

2. The Armor Cracked (Membrane Remodeling)

Remember the "tank" armor? The cell membrane was stiff and rigid.

• The Effect: Without the 3-MST gas, the membrane turned into butter. It became too fluid and floppy.
• The Result: This made the cell vulnerable. It was like taking the armor off a knight and replacing it with wet paper. The cell couldn't hold its shape or protect itself anymore.

3. The "Rust" Attack (Ferroptosis)

This is the most dramatic part. Because the membrane was now floppy and full of the wrong kind of fats, it started to rust.

• The Analogy: Imagine a car with a new, shiny paint job. If you remove the protective wax and leave it out in the rain, it rusts quickly.
• The Science: The cell started to accumulate "rust" (lipid peroxidation). The cell's internal rust-removal system (GPX4) broke down, and the rust spread until the cell literally fell apart. This specific type of death is called ferroptosis.

---

The "Domino Effect" on the Whole Cell

The researchers didn't just look at one thing; they looked at the whole cell's blueprint (DNA, proteins, and fats) to see what was happening. They found a massive chain reaction:

1. The Factory Shut Down: The instructions for building the cell's energy machines were deleted.
2. The Stress Alarm Sounded: The cell realized it was dying and tried to scream for help (activating stress pathways), but it was too late.
3. The "Boss" Lost Power: The signals that told the cancer to keep growing (Wnt signaling) were turned off. The "Cancer Boss" lost its authority.

Why This Is a Big Deal

For years, doctors have struggled to kill these "Cancer Bosses" because they are too quiet and too tough.

• Old Strategy: Try to kill fast-growing cells (Chemotherapy). Result: Misses the bosses.
• New Strategy: Target the 3-MST power plant.
  • It doesn't matter if the cell is sleeping or awake; it needs this specific machine to survive.
  • When you break it, the cell doesn't just stop growing; it undergoes a total system failure and dies a messy, "rusty" death.

The Bottom Line

This paper suggests that 3-MST is the "Achilles' Heel" of colorectal cancer stem cells. By using a drug to shut down this specific enzyme, we can force these stubborn, therapy-resistant cells to collapse from the inside out. It's like finding the one specific key that unlocks the door to the dragon's cave, allowing us to finally defeat the cancer that keeps coming back.

Technical Summary

1. Problem Statement

Colorectal cancer (CRC) recurrence and therapeutic resistance are largely driven by Cancer Stem Cells (CSCs). These cells possess self-renewal capabilities, are often quiescent (dormant), and exhibit high resistance to conventional chemotherapy (e.g., taxanes). Current therapies fail to eliminate CSCs effectively because they target rapidly dividing cells, whereas CSCs rely on unique metabolic adaptations to survive in low-bioenergetic states. The specific metabolic vulnerabilities of colorectal CSCs remain poorly defined, necessitating the discovery of novel therapeutic targets that can selectively eliminate this resistant population.

2. Methodology

The study employed a multi-disciplinary approach combining genetic, pharmacological, and multi-omics strategies to investigate the role of 3-mercaptopyruvate sulfurtransferase (3-MST), an enzyme involved in hydrogen sulfide (H₂S) and reactive sulfur species (RSS) production.

• Cell Models:
  • Parental Cells: HCT116, LoVo, and SW620 colorectal cancer cell lines.
  • CSC Models: CSCs were enriched from parental lines using non-adherent, serum-free culture conditions (tumorsphere formation).
  • Rescue Models: CSCs re-differentiated under specific conditions to serve as a phenotypic control.
  • Genetic Manipulation: Generation of MPST-deficient (3-MST knockout) cell lines using CRISPR/Cas9 and a codon-optimized rescue construct.
• Pharmacological Intervention: Treatment with HMPSNE, a specific small-molecule inhibitor of 3-MST.
• In Vivo Models: Subcutaneous xenografts in humanized NSG mice using CSC-derived tumors to assess tumor growth inhibition.
• Multi-Omics Profiling:
  • Transcriptomics: RNA-seq analysis.
  • Proteomics: Data-independent acquisition (DIA) mass spectrometry.
  • Metabolomics: Targeted HILIC-MS/MS for central carbon metabolism.
  • Lipidomics: HILIC-ESI-MS/MS for comprehensive lipid species quantification.
• Functional Assays:
  • Bioenergetics: Seahorse XF analysis (OCR for respiration, ECAR for glycolysis).
  • Biophysics: Membrane fluidity measurements using excimer/monomer fluorescence ratios.
  • Cell Death: Flow cytometry for apoptosis/necrosis, ROS, and reactive sulfur species (H₂Sn) detection.
  • Stemness: Spheroid formation assays, migration (wound healing), and surface marker analysis (CD133, CD44, LGR5, etc.).

3. Key Contributions

• Identification of 3-MST as a CSC Vulnerability: The study establishes that 3-MST is markedly upregulated in colorectal CSCs compared to differentiated tumor cells and normal epithelium, functioning as a critical metabolic support mechanism.
• Mechanism of Selective Lethality: It demonstrates that CSCs operate in a "metabolically restrained" state (low glycolysis and oxidative phosphorylation) where 3-MST is essential for maintaining minimal bioenergetic homeostasis. Inhibition of 3-MST causes a catastrophic bioenergetic collapse specifically in CSCs, while parental cells retain residual activity.
• Integration of Metabolic and Lipid Remodeling: The paper links 3-MST inhibition to profound lipid remodeling, specifically increasing membrane fluidity and susceptibility to lipid peroxidation, thereby sensitizing CSCs to ferroptosis.
• Multi-Omics Validation: Provides a comprehensive dataset (transcriptome, proteome, metabolome, lipidome) detailing the molecular cascade triggered by 3-MST inhibition, including the suppression of Wnt/β-catenin signaling and activation of integrated stress responses.

4. Key Results

A. 3-MST is Upregulated and Essential in CSCs

• 3-MST expression correlates strongly with proliferation rates in CRC cell lines and is significantly higher in CSCs than in parental or rescue cells.
• CSCs exhibit a unique phenotype: rigid membranes, low ROS, high reactive sulfur species (H₂Sn), and reduced bioenergetic flux (low basal respiration and glycolysis).
• Genetic knockout or pharmacological inhibition (HMPSNE) of 3-MST significantly impairs CSC proliferation, spheroid formation (stemness), and migration, while having a less severe effect on parental cells.

B. Bioenergetic Collapse

• Parental Cells: HMPSNE treatment reduces respiration and glycolysis but leaves residual bioenergetic activity.
• CSCs: HMPSNE treatment leads to a near-complete suppression of both oxidative phosphorylation and glycolysis. This "metabolic collapse" is the primary driver of cell death in CSCs, as they lack the metabolic flexibility to compensate.

C. Lipid Remodeling and Ferroptosis Susceptibility

• Membrane Fluidity: 3-MST inhibition increases membrane fluidity in CSCs (reversing their characteristic rigidity).
• Lipid Composition:
  • Depletion of protective phospholipids and cholesterol.
  • Accumulation of ceramides, sphingolipids, and free fatty acids.
  • Downregulation of SCD (Stearoyl-CoA desaturase), reducing monounsaturated fatty acids that normally protect against lipid peroxidation.
  • Upregulation of PEBP1, which facilitates lipid peroxidation.
• Ferroptosis Markers: Inhibition leads to reduced GPX4 (a key ferroptosis suppressor) and increased SAT1 and HMOX1. The combination of increased lipid peroxidation potential and impaired antioxidant defense drives ferroptotic cell death.

D. Stress Pathways and Signaling

• Integrated Stress Response (ISR): Activation of ER stress, unfolded protein response (UPR), and oxidative stress pathways (ATF3, CHOP, GADD45B).
• Wnt/β-catenin Suppression: 3-MST inhibition downregulates Wnt signaling components (WNT16, TCF7L2, CCND1), a pathway critical for CSC maintenance.
• Mixed-Mode Cell Death: The data suggests a convergence of apoptosis, ferroptosis, and necrosis, driven by metabolic failure and proteotoxic stress.

E. In Vivo Efficacy

• Systemic administration of HMPSNE in a murine xenograft model significantly reduced the growth of CSC-derived tumors, confirming the therapeutic potential of targeting 3-MST.

5. Significance

• Therapeutic Strategy: This study identifies 3-MST as a novel, translatable therapeutic target for eliminating therapy-resistant colorectal CSCs. Unlike conventional chemotherapies that fail against quiescent CSCs, 3-MST inhibition exploits a specific metabolic dependency.
• Mechanistic Insight: It reveals that CSCs rely on 3-MST not just for H₂S production, but for maintaining mitochondrial protein homeostasis, membrane integrity, and redox balance.
• Overcoming Resistance: By inducing a "metabolic collapse" and sensitizing cells to ferroptosis, this approach offers a strategy to bypass the dormancy and chemoresistance mechanisms that typically allow CSCs to drive tumor recurrence.
• Biomarker Potential: The upregulation of 3-MST in human tumor tissues suggests it could serve as a biomarker for identifying patients who may benefit from 3-MST-targeted therapies.

In conclusion, the paper provides robust evidence that 3-MST is a linchpin in the survival of colorectal cancer stem cells. Targeting this enzyme disrupts the delicate metabolic and structural balance of CSCs, leading to their selective elimination via a mixed-mode cell death mechanism dominated by ferroptosis and bioenergetic failure.